Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2020

Kudo Y, Sugimoto M, Arias E, Kasashima H, Cordes T, Linares JF, et al. PKCλ/ι Loss Induces Autophagy, Oxidative Phosphorylation, and NRF2 to Promote Liver Cancer Progression. Cancer Cell. 2020;38(2):247-262.e11.

Zhang S, Chiang GC, Knapp JM, Zecca CM, He D, Ramakrishna R, et al. Grading meningiomas utilizing multiparametric MRI with inclusion of susceptibility weighted imaging and quantitative susceptibility mapping. J Neuroradiol. 2020;47(4):272-277.

Alam T, Agrawal S, Severin J, Young RS, Andersson R, Arner E, et al. Comparative transcriptomics of primary cells in vertebrates. Genome Res. 2020;30(7):951-961.

Haas T, Cushing MM. Hemostatic Balance in Severe Trauma. Front Pediatr. 2020;8:600501.

Tosi U, Kommidi H, Adeuyan O, Guo H, Maachani UB, Chen N, et al. PET, image-guided HDAC inhibition of pediatric diffuse midline glioma improves survival in murine models. Sci Adv. 2020;6(30):eabb4105.

Holst JM, Plesner TL, Pedersen MB, Frederiksen H, Møller MB, Clausen MR, et al. Myeloproliferative and lymphoproliferative malignancies occurring in the same patient: a nationwide discovery cohort. Haematologica. 2020;105(10):2432-2439.

Amara SN, Kuiken HJ, Selfors LM, Butler T, Leung ML, Leung CT, et al. Transient commensal clonal interactions can drive tumor metastasis. Nat Commun. 2020;11(1):5799.

Geyer JT, Margolskee E, Krichevsky SA, Cattaneo D, Boiocchi L, Ronchi P, et al. Disease progression in myeloproliferative neoplasms: comparing patients in accelerated phase with those in chronic phase with increased blasts (<10%) or with other types of disease progression. Haematologica. 2020;105(5):e221-e224.

Droesch C, Do MH, DeSancho M, Lee E-, Magro C, Harp J. Livedoid and Purpuric Skin Eruptions Associated With Coagulopathy in Severe COVID-19. JAMA Dermatol. 2020;156(9):1-3.

Lui GY, Shaw R, Schaub FX, Stork IN, Gurley KE, Bridgwater C, et al. BET, SRC, and BCL2 family inhibitors are synergistic drug combinations with PARP inhibitors in ovarian cancer. EBioMedicine. 2020;60:102988.